within Pharmacolibrary.Drugs.ATC.L;

model L01FD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.235 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 840 / 1000000,
    adminCount     = 1,
    Vd             = 0.00311,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pertuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). It is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. Pertuzumab is approved for clinical use and is part of the standard of care in HER2-positive breast cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from population pharmacokinetic analysis, adult cancer patients (mainly breast cancer), mostly female, typical clinical dosing.</p><h4>References</h4><ol><li><p>Tan, AR, et al., &amp; Jackisch, C (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>The Lancet. Oncology</i> 22(1) 85–97. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(20)30536-2&quot;>10.1016/S1470-2045(20)30536-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33357420/&quot;>https://pubmed.ncbi.nlm.nih.gov/33357420</a></p></li><li><p>Luo, Y, et al., &amp; Xu, B (2019). Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-cancer drugs</i> 30(8) 866–872. DOI:<a href=&quot;https://doi.org/10.1097/CAD.0000000000000808&quot;>10.1097/CAD.0000000000000808</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31305270/&quot;>https://pubmed.ncbi.nlm.nih.gov/31305270</a></p></li><li><p>Yang, J, et al., &amp; Hu, W (2022). HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 36(3) 393–409. DOI:<a href=&quot;https://doi.org/10.1007/s40259-022-00534-w&quot;>10.1007/s40259-022-00534-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35594017/&quot;>https://pubmed.ncbi.nlm.nih.gov/35594017</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FD02;
